Pharma industry executives expect the recent GST rate cut to serve as a booster for contract manufacturers, while on the issue of input tax credit (ITC) — arising from the 18 per tax on APIs — leaders suggest that faster processing of refunds could help to recover the invested capital and ease tax liability.
Browsing: Market & Financials
Market trends, financial performance, quarterly results, and investment insights from global pharma and biotech companies.
Cipla Q1 earnings beat forecast, leading to a rise in shares. The financial performance highlights growth in India.
Amgen to build $600m science and innovation centre in the US
Atlas Venture, one of the mainstay biotech venture capital firms, has collected its second batch of money within the past nine months.
Aurobindo Pharma invested USD 145 million in its China facility. • The plant commenced operations in November 2024. • Break-even at EBITDA level is expected by